UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39445 MSP Recovery, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-4117825 (State or other jurisdiction ...

[Highlights](index=1&type=section&id=Highlights) ICMB reported a NAV of $5.27 per share, $0.08 million net investment income, and declared a $0.14 per share total distribution Key Financial Metrics | Metric | Value (in millions) | | :--- | :--- | | Total assets | $224.1 million | | Investment portfolio, at fair value | $204.1 million | | Net assets | $76.0 million | | Net asset value per share | $5.27 | | Weighted average yield on debt investments | 10.57% | | Net investment income before taxes (NII) | $0.8 million | | NII per share | $0.06 | | Net decrease in net assets from operations | (\$0.4) million | | Net decrease in net assets from operations per share | (\$0.03) | | Distributions paid per common share | $0.12 | - The Board of Directors declared a regular quarterly distribution of **$0.12** per share and a supplemental distribution of **$0.02** per share for the quarter ending September 30, 2025[4](index=4&type=chunk) - Net asset value (NAV) per share decreased by **$0.15** to **$5.27** as of June 30, 2025, compared to **$5.42** as of March 31, 2025[4](index=4&type=chunk) - During the quarter, ICMB invested **$19.0 million** and fully realized investments in three portfolio companies, generating an internal rate of return (IRR) of **32.82%** on these exits[4](index=4&type=chunk) - The weighted average yield on debt investments decreased slightly to **10.57%** from **10.95%** in the previous quarter[4](index=4&type=chunk) [Financial and Operational Performance](index=2&type=section&id=Financial%20and%20Operational%20Performance) The company declared a $0.14 per share distribution, invested $19.0 million, and maintained a portfolio primarily in first lien and floating rate debt [Distributions](index=2&type=section&id=Distributions) - The Board declared a distribution of **$0.12** per share for the quarter ending September 30, 2025, plus a supplemental distribution of **$0.02** per share, both payable on October 9, 2025[7](index=7&type=chunk) - This total distribution represents a **20.07%** yield on the company's share price as of June 30, 2025 The company does not expect the distribution to be comprised of a return of capital[8](index=8&type=chunk) [Portfolio and Investment Activities](index=2&type=section&id=Portfolio%20and%20Investment%20Activities) - Invested a total of **$19.0 million** in one new and four existing portfolio companies during the quarter, with new debt investments made at a weighted average yield of **9.03%**[9](index=9&type=chunk) - Received **$10.0 million** in proceeds from repayments, sales, and amortization, primarily from the realization of three investments[10](index=10&type=chunk) - Net realized and unrealized losses resulted in a decrease in net investments of approximately **$1.0 million**, or **$0.07** per share[11](index=11&type=chunk) - As of June 30, 2025, the portfolio consisted of investments in **43** companies, with **79.23%** in first lien investments and **98.50%** of the debt portfolio in floating rate investments[12](index=12&type=chunk) [Capital Resources](index=2&type=section&id=Capital%20Resources) - As of June 30, 2025, the Company had **$17.3 million** in cash (**$14.4 million** restricted) and **$29.5 million** of unused capacity under its revolving credit facility[13](index=13&type=chunk) [Subsequent Events and Corporate Actions](index=2&type=section&id=Subsequent%20Events%20and%20Corporate%20Actions) Post-quarter, the company invested an additional $0.2 million, declared a Q3 2025 distribution, and authorized a new $5 million share repurchase program - Between June 30, 2025, and August 13, 2025, the Company invested an additional **$0.2 million** in two existing portfolio companies[14](index=14&type=chunk) - On August 7, 2025, the Board authorized a new share repurchase program of up to **$5 million**, effective for one year until August 7, 2026[16](index=16&type=chunk) [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) The consolidated statements detail total assets of $224.1 million, net assets of $76.0 million, and a net decrease in assets from operations of (\$0.4) million [Consolidated Statements of Assets and Liabilities](index=4&type=section&id=Consolidated%20Statements%20of%20Assets%20and%20Liabilities) Consolidated Assets and Liabilities | (in thousands) | June 30, 2025 (Unaudited) (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | Total investments, at fair value | $204,131 | $191,617 | | Total Assets | $224,065 | $206,852 | | Debt, net | $134,385 | $122,042 | | Total Liabilities | $148,080 | $129,250 | | Total Net Assets | $75,984 | $77,602 | | Net Asset Value Per Share | $5.27 | $5.39 | [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Consolidated Operations Summary | For the three months ended June 30, | 2025 (in thousands) | 2024 (in thousands) | | :--- | :--- | :--- | | Total investment income | $4,545,199 | $5,119,319 | | Net expenses | $3,711,141 | $3,864,957 | | Net investment income after taxes | $604,148 | $1,309,102 | | Net realized and unrealized gain/(loss) | (\$1,038,446) | (\$3,261,248) | | Net increase (decrease) in net assets from operations | (\$434,298) | (\$1,952,146) | | Earnings per share (Basic and diluted) | (\$0.03) | (\$0.14) | [Company Overview and Disclosures](index=6&type=section&id=Company%20Overview%20and%20Disclosures) The company is an externally managed BDC focused on middle-market investments, with the report including standard forward-looking statement disclaimers - The Company is an externally managed BDC with an investment objective to maximize total return via current income and capital appreciation from debt and equity investments in middle-market companies[19](index=19&type=chunk) - The report contains forward-looking statements that are based on current expectations and are subject to substantial risks and uncertainties, and actual results may differ materially[20](index=20&type=chunk)[21](index=21&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38613 _________________________________________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 33-0827593 (State or other jurisdic ...

Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3 million at Q2 2025; runway through at least 2027 - • Dabogratinib (formerly TYRA-300) is an oral investigational FGFR3-selective inhibitor being developed for the treatment of IR NMIBC and ACH. o Dosed first patient in Phase 2 NMIBC Study – SURF302. SURF30 ...

Exhibit 99.1 Jefferson Capital Reports Second Quarter 2025 Results 47% Growth in Revenue to $152.7 Million Collections Grow 85% to $255.7 Million with Estimated Remaining Collections ("ERC") up 31% to a Record $2.9 Billion Pre-tax Income up 82% to $62.0 Million with Net Income up 48% to $47.7 Million Adjusted Pre-tax Income up 55% to $61.7 Million Board of Directors Declares Quarterly Cash Dividend of $0.24 per Share MINNEAPOLIS, August 14, 2025 /GLOBE NEWSWIRE/ -- Jefferson Capital, Inc. ("Jefferson Capita ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _________________ to ___________________ Commission File Number: 001-40730 DRAGONFLY ENERGY HOLDINGS CORP. (Exact name of registrant as specified in its charter) | Ne ...

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 | | | Name of each exchange on which | | --- | --- | --- | | Title of each cl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 4, 2025 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) Registrant's telephone number, including area code: (833) 723-2021 Securities registered pursuant to Section 12(b) of the Act: OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Emp ...